Prospective study in a group of patients with COVID-19 pneumonia.
Objective:
Assessment of pulmonary and heart dysfunction, fibrosis-related markers and antibodies as
well as the search for risk factors for an unfavorable course and possible complications
in patients after pneumonia due to SARS-CoV-2 (COVID-19) infection.
Patients:
A group of approx. 100 patients assessed shortly after pneumonia and followed up,
investigated after 3 and 6 months with possible prolongation to 12 months.
Inclusion Criteria:
1. Confirmed SARS-CoV-2 infection with pneumonia hospitalized
2. Two negative PCR results of a swab from the respiratory tract in succession,
including the last one taken no later than 3 days before the planned lung function
tests (1st visit).
Exclusion Criteria:
1. Lack of patient consent,
2. Present contraindications for lung function tests
3. Inability to perform correctly lung function measurements
National Institute for Tuberculosis and Lung Diseases
Warsaw, Mazowieckie, Poland
Piotr W Boros, MD, PhD, Principal Investigator
National TB & Lung Diseases Research Institute